Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice

Amber B. KoehlerDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Nelson LeungDivision of Nephrology, Mayo Clinic, Rochester, MN, USA;

Timothy G. CallDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Kari G. RabeDivision of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA;

Sara J. AchenbachDivision of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA;

Wei DingDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Saad S. KenderianDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Jose F. LeisDepartment of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA;

Yucai WangDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Eli MuchtarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Suzanne R. HaymanDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Paul J. HampelDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Heidi D. FinnesDepartment of Pharmacy Cancer Care, Mayo Clinic, Rochester, MN, USA

Susan M. SchwagerDivision of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA;

Susan L. SlagerDivision of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA;

Neil E. KayDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

Sameer A. ParikhDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Correspondence[email protected]

References